Theresa celebrated 100 months on her phase 1 clinical trial – Sarah Cannon Research Institute
Sarah Cannon Research Institute shared the following post on LinkedIn:
“Several years ago, Theresa noticed a knot in her right breast, but at the time, she was caring for her mother and delayed visiting her doctor. Following her mother’s passing, Theresa noticed a new lump growing on the crown of her head and scheduled a biopsy with a dermatologist, which revealed a malignant growth. This ultimately led to her being diagnosed with stage 4 metastatic breast cancer.
Following further testing, Theresa’s primary doctor explained that she was a candidate for a clinical trial at Sarah Cannon Research Institute (SCRI) in Nashville, Tenn., where she met Erika Hamilton, MD, Director, Breast Cancer Research; Executive Chair, Breast Cancer Research Committee, SCRI, and began her clinical trial treatment journey under Dr. Hamilton’s supervision using a hormone blocker in combination with a PI3 kinase inhibitor in the first-line setting.
Theresa continues the trial with no visible disease on scans and has maintained a thriving and full life in her retirement. In fact, Theresa recently celebrated 100 months on her phase 1 clinical trial, and the care team at SCRI in Nashville surprised her with a cake to honor this incredible moment.”